Avatar Robots: The Next Hype Cycle for Humanoid Robots Is Drawing Near

An 'avatar'—literally a 'body outside the self'—essentially keeps human cognition and judgment remote while transforming robots into physical vessels that humans can inhabit. Operators input movements or intentions to the robot via motion capture, VR, visual feedback, and haptic (force) feedback systems; the robot’s onboard 'cerebellum' handles balance, joint coordination, and execution of motions. Initially, control is 100% teleoperated by humans; as AI advances, human involvement gradually declines: 100% teleoperation → 50% → 10% → 1% for exceptional intervention only. Ultimately, this evolves into a 'human-in-the-loop' architecture where 'the robot acts first; humans step in only for tasks it cannot handle.' This trajectory closely mirrors the feedback loop in AI-powered coding: a coding agent writes code first, then compiles and tests it—flagging errors for human correction. Similarly, an avatar robot executes actions autonomously; upon failure, it requests human takeover—and each such handover becomes exceptionally valuable training data. The more robots deployed, the richer the failure dataset, the stronger the AI becomes, and the lower the human intervention rate drops. Commercially, this approach sidesteps the most difficult hurdle facing fully autonomous robots: robots need not achieve near-human-level general intelligence before delivering tangible productivity. Moreover, capital markets require far less rigorous validation than true commercialization demands. 'Avatar' demos are proliferating rapidly. Any single demo holds limited significance—but when multiple companies repeatedly showcase the same technical pathway, its nature shifts. Since 2025, this shift has become markedly evident. Westlake Robotics is the domestic company most explicitly betting on this path. Its GAE (General Avatar Engine) system feeds real-time human motion into a universal locomotion model, then maps it onto diverse robot bodies. This year’s Titan o1 release further integrates GAE with Westlake’s proprietary full-size humanoid robot, demonstrating millisecond-level motion mapping, cross-platform control, and remote teleoperation across ~1,300 kilometers. Westlake has officially adopted 'Avatar—Always at Your Side' as its core product slogan. Unitree Technology unveiled its 'Full-Body Teleoperation Platform' in November 2025—and likewise used the term 'avatar' in its official communications. In demonstrations, its G1 robot performed dishwashing, cleaning, laundry folding, and tray-carrying under human teleoperation. As one of China’s most influential humanoid robot hardware developers, Unitree’s adoption of this technology significantly bolsters its credibility as an industry-standard module. At this year’s World Robot Conference, China North Industries Group Corporation (Norinco) further elevated the narrative weight of this pathway. China Norinco Intelligent Innovation Research Institute showcased its 'Fuxi' special-purpose humanoid robot, directly paired with an 'avatar' teleoperation system designed for 90-kg full-size platforms—enabling real-time human motion remapping and whole-body coordinated control for applications including remote reconnaissance, hazardous-area operations, and specialized emergency response. Meanwhile, Norinco subsidiary Wuba Intelligence demonstrated cross-regional remote human-robot collaborative operations with its 'Dasheng' robot. What began as startup-level technical experimentation has now entered the state-owned enterprise (SOE) special-robotics ecosystem. Stellar Dynamics also publicly demonstrated L7 full-body teleoperation capabilities at the 2026 World Robot Conference—and explicitly defined motion data and human-robot interaction logs generated through teleoperation as critical data sources for training embodied world models and Vision-Language-Action (VLA) policies.

Westlake Accelerates! Unveiling Westlake University’s First Industry-Academia Collaboration Achievement—from Academic Circles to the Broader Public

On June 2, Westlake University officially announced that Westlake Biomedicine Technology (Hangzhou) Co., Ltd. had successfully closed a nearly RMB 100-million Pre-A round financing. This marks the formal commercialization of Westlake University’s first research-to-industry translation project. According to Westlake University’s announcement, the company’s core technology originates from the laboratory of Professor Xiao-Fei Gao, which developed a novel personalized red blood cell (RBC) therapy capable of treating rare diseases—including gout, hemophilia, pure red cell aplasia, and phenylketonuria. This milestone occurred just two years and three months after Westlake University received official approval to establish. While some were still inquiring how Westlake University admits students, and others continued questioning whether social donations alone could sustain its high-investment, low-return basic scientific research, this compact yet elite new university had already quietly brought a cutting-edge research project to market. Why did they move so fast? A fundraising campaign for rare-disease research On the last day of October 2018, a donation appeal jointly issued by the Hangzhou Daily and the Westlake Education Foundation spread widely across Hangzhou residents’ WeChat circles—the initiative was titled the 'Westlake Rare Disease Research Special Program.' Of the world’s 7,000 known rare diseases, only 5% have approved treatments. This fundraising campaign offered the public its first glimpse behind Westlake University’s mysterious gates. Dr. Xiao-Fei Gao holds a Ph.D. from the University of Kansas School of Medicine and completed postdoctoral training at MIT. As one of Westlake University’s earliest recruited senior scholars, he established the Stem Cell and Organ Regeneration Laboratory and successfully developed a novel personalized red blood cell therapy—using stem cells derived from human venous blood to engineer RBCs carrying targeted therapeutics, enabling treatment of various severe diseases. Dr. Xiao-Fei Gao Take gout treatment as an example: we know uricase can lower uric acid levels—but endogenous uricase in humans is extremely low. Dr. Gao’s lab leveraged the novel RBC therapy to 'hitchhike' higher doses of uricase into the body aboard red blood cells, thereby enhancing therapeutic efficacy. Applying the same principle, hemophilia could theoretically be treated by loading clotting factors into RBCs—offering safer, longer-lasting, and more effective therapy for patients. Dr. Gao remarked: 'Today’s biotechnology is evolving much like software did decades ago—gradually permeating every industry. We aspire to participate in this transformative process, ultimately realizing our mission: curing complex diseases and extending human lifespan.' An 80-year-old Hangzhou grandmother donating—Source: Hangzhou Daily Treating rare diseases and saving lives—this research commands deep respect. Hangzhou citizens contributed RMB 10, 100, and 1,000 yuan apiece, raising a total of RMB 998,900. Though hopeful, few imagined that just 19 months later, this technology would truly enter the market. A parallel track supporting lab-to-market transition Statistics show that fewer than 5% of patents held by Chinese research institutions and universities ever achieve commercial application. Most domestic universities track and translate research outcomes only as far as patent registration—with little to no follow-up on actual commercial deployment. By contrast, Stanford University filed 252 patents in 2011 and licensed 101 of them—a 40% licensing rate. As of 2015, UC Irvine held over 400 patents and had commercialized 143—achieving a 35.75% commercialization rate.

Westlake Plans Full-Capacity US Operations with No Major Second-Half Turnarounds

Aug 4, 2026

Westlake aims to maximize asset utilization in its US plastic and chlor-alkali plants without major turnarounds in the second half. The company also plans to integrate newly acquired German PVC sites using low-cost US feedstock.

icis

2026-02-24

Westlake looks to ‘self-help’ to drive earnings, but also eyes better demand

2026-08-04

Westlake Plans Full-Capacity US Operations with No Major Second-Half Turnarounds

Westlake Plans Full-Capacity US Operations with No Major Second-Half Turnarounds

FAQ